A case of acute fulminant multiple sclerosis treated with alemtuzumab

被引:10
|
作者
Gobbin, F. [1 ]
Marangi, A. [1 ]
Orlandi, R. [1 ]
Richelli, S. [2 ]
Turatti, M. [3 ]
Calabrese, M. [1 ]
Forgione, A. [4 ]
Alessandrini, F. [5 ]
Benedetti, M. D. [3 ]
Monaco, S. [1 ]
Gajofatto, A. [1 ]
机构
[1] Univ Verona, Dept Neurosci Biomed & Movement Sci, Verona, Italy
[2] Osped Sacro Cuore, Unit Intens Rehabil, Verona, Italy
[3] Azienda Osped Univ Integrata, Unit Neurol B, Verona, Italy
[4] Casa Cura Pederzoli, Unit Neurol, Verona, Italy
[5] Azienda Osped Univ Integrata, Unit Neuroradiol, Verona, Italy
关键词
Fulminant multiple sclerosis; Marburg's variant multiple; Sclerosis; Alemtuzumab;
D O I
10.1016/j.msard.2017.06.007
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
We describe the case of a woman who came to our attention for acute onset and very rapidly worsening left hemiplegia, vision loss and cognitive impairment. MRI, laboratory and clinical investigations were highly suggestive of an active inflammatory demyelinating disease. Following exclusion of other possible etiologies, a diagnosis of Marburg's variant multiple sclerosis was made. After repeated high-dose steroids and plasma-exchange, the patient was treated with a first course of alemtuzumab followed by improvement of the clinical and MRI picture. This is the first reported case of Marburg type multiple sclerosis treated with alemtuzumab.
引用
收藏
页码:9 / 11
页数:3
相关论文
共 50 条
  • [21] Risk of opportunistic infections in patients treated with alemtuzumab for multiple sclerosis
    Buonomo, Antonio Riccardo
    Zappulo, Emanuela
    Viceconte, Giulio
    Scotto, Riccardo
    Borgia, Guglielmo
    Gentile, Ivan
    EXPERT OPINION ON DRUG SAFETY, 2018, 17 (07) : 709 - 717
  • [22] Myelodysplastic syndrome in an alemtuzumab-treated multiple sclerosis patient
    Jean Hee Kim
    Silvia Park
    Woojun Kim
    Neurological Sciences, 2022, 43 : 5651 - 5653
  • [23] Cytomegalovirus primary infection in a patient with multiple sclerosis treated with alemtuzumab
    Aguirre, Clara
    Meca-Lallana, Virginia
    Sanchez, Pedro
    Vivancos, Jose
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2019, 35 : 270 - 271
  • [24] FOLLOW UP EXAMINATION OF MULTIPLE SCLEROSIS PATIENTS TREATED WITH ALEMTUZUMAB IN MULTIPLE SCLEROSIS CENTRE, SZEGED
    Fricska-Nagy Zsanett
    Fuvesi Judit
    Kincses Zsigmond Tamas
    Legradi Dora
    Vecsei Laszlo
    Klivenyi Peter
    Bencsik Krisztina
    IDEGGYOGYASZATI SZEMLE-CLINICAL NEUROSCIENCE, 2022, 75 (11-12): : 377 - 384
  • [25] Alemtuzumab for Multiple Sclerosis
    Mark D. Willis
    Neil P. Robertson
    Current Neurology and Neuroscience Reports, 2016, 16
  • [26] Alemtuzumab for multiple sclerosis
    Riera, Rachel
    Porfirio, Gustavo J. M.
    Torloni, Maria R.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2016, (04):
  • [27] Alemtuzumab for multiple sclerosis
    Riera, Rachel
    Torloni, Maria Regina
    Martimbianco, Ana Luiza C.
    Pacheco, Rafael L.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2023, (06):
  • [28] Alemtuzumab in Multiple Sclerosis
    Azzopardi, Laura
    Coles, Alasdair
    NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY, 2011, 48 : 79 - 82
  • [29] Alemtuzumab for Multiple Sclerosis
    Willis, Mark D.
    Robertson, Neil P.
    CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2016, 16 (09)
  • [30] Case Report: Adult Still's Disease in an Alemtuzumab-Treated Multiple Sclerosis Patient
    Kraemer, Julia
    Kroemer-Olbrisch, Tanja
    Lakomek, Heinz-Juergen
    Schellinger, Peter D.
    Foell, Dirk
    Meuth, Sven G.
    Straeten, Vera
    FRONTIERS IN IMMUNOLOGY, 2020, 11